[Child osteoarticular infections: statements and perspectives].
Cohen
R
R
Grimprel
E
E
D000284:Administration, Oral; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001170:Arthritis, Infectious / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D001427:Bacterial Toxins; D002648:Child; D002986:Clinical Trials as Topic; D004630:Emergencies; D005098:Exotoxins; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D017882:Kingella kingae / Q000187:drug effects*; D007956:Leukocidins; D016106:Methicillin Resistance; D016870:Neisseriaceae Infections / Q000175:diagnosis / Q000188:drug therapy*; D010019:Osteomyelitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity; D013997:Time Factors
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin